The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow

Guekht, Alla; Mizinova, Maria; Kaimovsky, I.; Даниленко, О. А.; Bianchi, Elisa; Beghi, Ettore

doi:10.1016/j.yebeh.2016.08.031

Cited by 13 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, two-thirds of these "new" costs related to hospitalization. Similar patterns were observed in a prospective Russian study, 6 with direct medical costs due to newly diagnosed epilepsy outweighing direct medical costs of established and well-controlled epilepsy, at €782 and €646 per person, respectively. These studies do not, however, capture the out of pocket costs to patients, which can impose a substantial personal impact.…”

Section: Limitations Of This Studysupporting

confidence: 80%

Prospective multisite cohort study of patient‐reported outcomes in adults with new‐onset seizures

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Limitations Of This Studysupporting

confidence: 80%

Prospective multisite cohort study of patient‐reported outcomes in adults with new‐onset seizures

et al. 2021

View full text Add to dashboard Cite

show abstract

“…37–39 The contribution of ASM to DMC is similar to other countries, eg, 67% in Russia and 81% in Nigeria and has also been observed in other LMIC such as India. 14 , 16 , 20 , 21 , 40 The cost associated with ASM in our study may be at the high end as we used pricing of the branded substance as a reference. 39 …”

Section: Discussionmentioning

confidence: 99%

Epilepsy-Related Direct Medical and Direct Non-Medical Cost in Adult Patients Living with Epilepsy at a Tertiary Neurology Center in Rwanda

Teuwen¹,

Sebera²,

Murekeyiteto³

et al. 2023

CEOR

View full text Add to dashboard Cite

Objective Up to one in four patients living with epilepsy (PwE) mentions financial constraints as a reason for loss to follow-up at the Ndera tertiary neuropsychiatry hospital. Therefore, we evaluated the annual direct medical cost (DMC) and direct non-medical cost (DnMC) of epilepsy and calculated costs assuming different follow-up frequency. Materials and Methods DMC data were obtained from a descriptive retrospective study of medical records, pharmacy dispensation and hospital logs of PwE, following their initial consultation in 2018 and who adhered to the normal clinical practice of monthly consultations for one year. DnMC data were collected through structured interviews of PwE in a cross-sectional cohort in August 2020. DnMC included biomedical care costs (eg, transportation, hospitality) and non-biomedical costs (traditional healer visits). We report weighted means for total costs, health insurance costs, and out-of-pocket costs (OoP). Results Mean annual total cost was 389.4 US$, of which 226.2 US$ was covered by the Rwandan Health Insurance co-payment for DMC and 163.2 US$ was OoP paid by patients. Mean weighted annual DMC (n = 55) was 248.9 US$. Mean weighted annual DMC for medical consultations and antiseizure medication accounted for 30.7 US$ and 161.7 US$, respectively. Based on structured interviews (n = 69), mean weighted annual DnMC for biomedical care was 73.0 US$. Mean DnMC for traditional healer care was 67.6 US$. Weighted annual total OoP was 163.2 US$ or 20% of the GDP per capita. OoP consisted of 14% DMC co-payment, 45% biomedical DnMC, and 41% traditional healer DnMC. Conclusion Epilepsy-related costs at a tertiary center are an important economic burden for PwE and Rwandan Health Insurance. Biomedical and traditional healer DnMC constitute 86% of total OoP. Future prospective studies should evaluate outcomes and costs of reduced visit frequency, indirect costs, and costs of comorbidities.

show abstract

“…In our study, we used real-world data from China to ensure our results reflected reality. As we know, pharmacoeconomics evaluations are related to the economic level (11,28,(33)(34)(35), and from children to adults (36), and the proportions of cost components also differ. A study on the cost of medical care for epilepsy conducted in the US showed that the annual hospitalization cost for epilepsy was $22305, which was several times that of the other expenses (37).…”

Section: Discussionmentioning

confidence: 99%

“…The annual cost of epilepsy in children between 2003 and 2014 was approximately $5.8 billion in United States (US) (10). The severity of epilepsy is an important factor affecting healthcare costs (11). For example, the average annual cost of children with uncontrolled epilepsy ($30,343) is significantly higher than that of patients with stable epilepsy ($18,206) (12).…”

Section: Original Articlementioning

confidence: 99%

Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective

Hu¹,

Dai²

2022

Ann Transl Med

View full text Add to dashboard Cite

Background:The incidence of epilepsy is 41-187 per 100,000 person-year in children. The health care costs for children with uncontrolled epilepsy is a huge burden. Perampanel (PER) was effective, safety and well-tolerated as add-on therapy in pediatric patients aged 4 to <12 years with uncontrolled focal seizures.However, there is still limited evidence on cost-effectiveness of PER in pediatric patients. We aimed to evaluate the cost-effectiveness of PER as an add-on therapy for pediatric patients with uncontrolled focal seizures.Methods: A Markov model was established to conduct an analysis from the perspective of the Chinese health system and society. The incremental cost-effectiveness ratio (ICER) of patients using PER and conventional therapy versus patients using conventional therapy alone were estimated and compared. The transition probability of the response level, health state utility values, and costs were derived from clinical trials and the literature. Costs, including medical, drug, transportation and indirect costs, were calculated.We performed 1-way sensitivity analyses and probabilistic sensitivity analyses. A subgroup analysis of different ages was also conducted. Results:The base-case analysis indicated that compared to maintaining conventional therapy, adding PER as an adjuvant drug therapy had an increased cost of $3,449.85 over 5 years, with an incremental qualityadjusted life years (QALY) value of 0.40, resulting in an ICER of $8,582.58 per additional QALY. The health state utility value had the greatest effect on the ICER. The probabilistic sensitivity analyses showed that the probability of PER being cost-effective was 76.

show abstract

The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow

Cited by 13 publications

References 27 publications

Prospective multisite cohort study of patient‐reported outcomes in adults with new‐onset seizures

Prospective multisite cohort study of patient‐reported outcomes in adults with new‐onset seizures

Epilepsy-Related Direct Medical and Direct Non-Medical Cost in Adult Patients Living with Epilepsy at a Tertiary Neurology Center in Rwanda

Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective

Contact Info

Product

Resources

About